Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies.

Trial Profile

Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Sirolimus (Primary) ; Antithymocyte globulin; Fludarabine; Mycophenolic acid; Rituximab; Treosulfan
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Follicular lymphoma; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; T cell lymphoma; Transplant rejection
  • Focus Adverse reactions
  • Acronyms TrRaMM
  • Most Recent Events

    • 05 Jan 2013 Planned number of patients changed from 45 to 85 as reported by European Clinical Trials Database record.
    • 26 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top